Tag Archives: Mayank Mamtani

Analysts Offer Insights on Healthcare Companies: Fortress Biotech (NASDAQ: FBIO) and Baudax Bio (NASDAQ: BXRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fortress Biotech (FBIO – Research Report) and Baudax Bio (BXRX – Research Report) with bullish sentiments. Fortress Biotech (FBIO) B.Riley FBR analyst

B.Riley FBR Reaffirms Their Hold Rating on Acasti Pharma (ACST)

In a report released yesterday, Mayank Mamtani from B.Riley FBR maintained a Hold rating on Acasti Pharma (ACST – Research Report), with a price target of $2.00. The company’s shares closed last Monday at $0.57, close to its 52-week low

Arrowhead Research (ARWR) Gets a Buy Rating from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arrowhead Research (ARWR – Research Report) today and set a price target of $83.00. The company’s shares closed last Monday at $43.72. According to TipRanks.com, Mamtani is a 5-star analyst

B.Riley FBR Keeps Their Buy Rating on Novavax (NVAX)

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Novavax (NVAX – Research Report) today and set a price target of $12.00. The company’s shares closed last Monday at $8.08, close to its 52-week low of $3.54. According to

B.Riley FBR Sticks to Its Buy Rating for Fortress Biotech (FBIO)

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Fortress Biotech (FBIO – Research Report) today and set a price target of $9.00. The company’s shares closed last Monday at $2.64, close to its 52-week high of $2.84. According

Dicerna Pharma (DRNA) Received its Third Buy in a Row

After Citigroup and H.C. Wainwright gave Dicerna Pharma (NASDAQ: DRNA) a Buy rating last month, the company received another Buy, this time from B.Riley FBR. Analyst Mayank Mamtani maintained a Buy rating on Dicerna Pharma today and set a price